Compare Abeona Therapeutics Inc (ABEO) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Nuscale Power Corporation — how do they compare? Abeona Therapeutics Inc trades at $7.42 (market cap $421.19M), while Nuscale Power Corporation trades at $9.79 (market cap $4.06B). The key difference: Nuscale Power Corporation is far larger — about 9.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| ABEO | SMR | |
|---|---|---|
Market Cap | $421.19M | $4.06B |
Sector | Health | Utilities |
52-Week High | $7.45 | $53.43 |
52-Week Low | $4.17 | $7.59 |
Enterprise Value | $276.10M | $2.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
NuScale Power (SMR) trades at $9.76, up 6.32% in the last session, with a bullish technical signal from moving averages. The company reported a net loss of $355.79 million in 2025 on revenue of $31.48 million, with negative margins, while analyst consensus is a Buy with a $10.50 price target. Recent news highlights regulatory progress and AI-driven power demand as growth catalysts.
Outlook hinges on commercial deployment of small modular reactors, offering high upside if execution succeeds, but risks include persistent losses, revenue volatility, and project delays. The stock presents speculative growth potential amid significant operational and financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
